In HCC cells, a combined treatment involving suberoylanilide hydroxamic acid, a powerful HDAC inhibitor already used in clinical trials, and DLC1 transduction had a synergistic inhibitory effect on tumor cell proliferation and anchorage-independent growth (159). This evidence concerns the gene DLC1 and hepatocellular carcinoma.